Healthcare Equipment and Supplies
Company Overview of Respicardia, Inc.
Respicardia, Inc. develops implantable therapies to improve respiratory rhythm management and cardiovascular health of sleep disorder and heart failure patients. It offers remede system, an implantable stimulation device that delivers electrical pulses at night and restores a normal breathing pattern during sleep for patients with central sleep apnea. The company was formerly known as Cardiac Concepts, Inc. Respicardia, Inc. was founded in 2006 and is based in Minnetonka, Minnesota.
12400 Whitewater Drive
Minnetonka, MN 55343
Founded in 2006
Key Executives for Respicardia, Inc.
Vice President of Research and Development
Vice President of Clinical Affairs
Compensation as of Fiscal Year 2014.
Respicardia, Inc. Key Developments
Respicardia, Inc. Presents at 13th Annual MedTech Investing Conference, May-21-2014 09:05 AM
May 18 14
Respicardia, Inc. Presents at 13th Annual MedTech Investing Conference, May-21-2014 09:05 AM. Venue: Graves Hotel, 601 First Avenue North, Minneapolis, MN 55401, United States. Speakers: Danny Sachs, MD, Physician Entrepreneur – Amphora, Kspine, Mainstay.
Respicardia Announces Results of remede System Pilot Study for the Treatment of Central Sleep Apnea
Sep 23 13
Respicardia announced results from the remede System Pilot Study during the Heart Failure Society of America (HFSA) Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea (CSA). The remede System Pilot study represents the first prospective, multi-center, global trial to treat CSA. Implanted by electro physiologists using a procedure similar to the implantation of intracardiac devices, the remede system is designed to restore normal sleep and breathing to improve respiratory and cardiovascular health in patients with CSA. A total of 44 CSA patients were implanted with the system and completed 6 months of follow-up. Patients experienced a greater than 50% decrease in apnea-hypopnea index (AHI), improved oxygenation by over 50%, decreased arousals and improved quality of life. CSA is associated with increased mortality and hospitalization in heart failure (HF) patients. Studies show that CSA affects up to 40% of HF patients and 30% atrial fibrillation patients.
Respicardia Announces Enrollment of First Patients in Pivotal Trial of the Remede System for the Treatment of Central Sleep Apnea
Aug 19 13
Respicardia announced that the first patients have been enrolled in the pivotal trial to evaluate the remede system in patients with Central Sleep Apnea (CSA). The Respicardia pivotal trial is a randomized, controlled study to compare the use of the remede System with medical therapy versus medical therapy alone. Patients will be enrolled at 25 centers in the United States with additional centers in Europe. Dr. Maria Rosa Costanzo, Medical Director of the Midwest Heart Specialists Heart Failure Program and the Edwards Center for Advanced Heart Failure in Naperville, IL, serves as international principal investigator.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 27, 2014
August 29, 2013